Literature DB >> 15673745

Interaction between posaconazole and amphotericin B in concomitant treatment against Candida albicans in vivo.

Anthony Cacciapuoti1, Maya Gurnani, Judith Halpern, Christine Norris, Reena Patel, David Loebenberg.   

Abstract

The interaction of posaconazole and amphotericin B was evaluated in concomitant treatment of Candida albicans systemic infections in immunocompetent mice by using four strains of C. albicans with different susceptibilities to fluconazole. Posaconazole and amphotericin B were each tested at four dose levels alone and in all possible combinations against each C. albicans strain. Survival curves of mice treated with combinations of posaconazole and amphotericin B were statistically compared with those of mice treated with the component monotherapies. Of the 64 total combinations evaluated against the C. albicans strains (16 combinations per strain), 20.3% were more effective in prolonging mouse survival than both of the monotherapies, 45.3% were more effective than one of the monotherapies, and 32.8% were similar to both monotherapies. No evidence of antagonism was observed between posaconazole and amphotericin B in this mouse model, consistent with in vitro results against the same strains.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15673745      PMCID: PMC547236          DOI: 10.1128/AAC.49.2.638-642.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

1.  Impact of the order of initiation of fluconazole and amphotericin B in sequential or combination therapy on killing of Candida albicans in vitro and in a rabbit model of endocarditis and pyelonephritis.

Authors:  A Louie; P Kaw; P Banerjee; W Liu; G Chen; M H Miller
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

2.  Pharmacokinetics of SCH 56592, a new azole broad-spectrum antifungal agent, in mice, rats, rabbits, dogs, and cynomolgus monkeys.

Authors:  A A Nomeir; P Kumari; M J Hilbert; S Gupta; D Loebenberg; A Cacciapuoti; R Hare; G H Miller; C C Lin; M N Cayen
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

3.  Efficacies of high-dose fluconazole plus amphotericin B and high-dose fluconazole plus 5-fluorocytosine versus amphotericin B, fluconazole, and 5-fluorocytosine monotherapies in treatment of experimental endocarditis, endophthalmitis, and pyelonephritis due to Candida albicans.

Authors:  A Louie; W Liu; D A Miller; A C Sucke; Q F Liu; G L Drusano; M Mayers; M H Miller
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

4.  Interactions between triazoles and amphotericin B against Cryptococcus neoformans.

Authors:  F Barchiesi; A M Schimizzi; F Caselli; A Novelli; S Fallani; D Giannini; D Arzeni; S Di Cesare; L F Di Francesco; M Fortuna; A Giacometti; F Carle; T Mazzei; G Scalise
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

5.  In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida.

Authors:  A Cacciapuoti; D Loebenberg; E Corcoran; F Menzel; E L Moss; C Norris; M Michalski; K Raynor; J Halpern; C Mendrick; B Arnold; B Antonacci; R Parmegiani; T Yarosh-Tomaine; G H Miller; R S Hare
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

6.  Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model.

Authors:  D Andes; T Stamsted; R Conklin
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

7.  Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis.

Authors:  Russell E Lewis; Randall A Prince; Jingduan Chi; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

Review 8.  Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001.

Authors:  William J Steinbach; David A Stevens; David W Denning
Journal:  Clin Infect Dis       Date:  2003-10-01       Impact factor: 9.079

9.  Combination therapy of murine invasive candidiasis with fluconazole and amphotericin B.

Authors:  A M Sugar; C A Hitchcock; P F Troke; M Picard
Journal:  Antimicrob Agents Chemother       Date:  1995-03       Impact factor: 5.191

10.  Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis.

Authors:  D Andes; K Marchillo; R Conklin; Gopal Krishna; Farkad Ezzet; Anthony Cacciapuoti; David Loebenberg
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

View more
  6 in total

1.  Posaconazole enhances the activity of amphotericin B against Aspergillus hyphae in vitro.

Authors:  Susanne Perkhofer; Helene Lugger; Manfred P Dierich; Cornelia Lass-Flörl
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

Review 2.  Pharmacokinetic/pharmacodynamic profile of posaconazole.

Authors:  Yanjun Li; Ursula Theuretzbacher; Cornelius J Clancy; M Hong Nguyen; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

3.  The Role of New Posaconazole Formulations in the Treatment of Candida albicans Infections: Data from an In Vitro Pharmacokinetic-Pharmacodynamic Model.

Authors:  Maria-Ioanna Beredaki; Maiken Cavling Arendrup; David Andes; Johan W Mouton; Joseph Meletiadis
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

Review 4.  Posaconazole.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2005       Impact factor: 9.546

5.  Posaconazole: A new agent for the prevention and management of severe, refractory or invasive fungal infections.

Authors:  Andrea V Page; W Conrad Liles
Journal:  Can J Infect Dis Med Microbiol       Date:  2008-07       Impact factor: 2.471

6.  Combination of Posaconazole and Amphotericin B in the Treatment of Candida glabrata Biofilms.

Authors:  Célia F Rodrigues; Diana F Alves; Mariana Henriques
Journal:  Microorganisms       Date:  2018-12-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.